new version V2017

lung cancer (metastatic)
Description Results

     

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

angiogenesis inhibitors

aflibercept
Ramlau, 2012Aflibercept and Docetaxel Docetaxel -
bevacizumab
Johnson, 2004bevacizumabplatinum based CT -
Sandler, 2006bevacizumabplatinum based CT -
Herbst, 2007bevacizumabplatinum based CT -
Nishio, 2009bevacizumabplatinum based CT -
Reck, 2010bevacizumab -
Herbst, 2011bevacizumab + erlotiniberlotinib alone -
ceritinib
Goss, 2010cediranib carboplatin and paclitaxel -
Dy, 2013cediranib gemcitabine and carboplatin -
Laurie, 2014cediranib carboplatin and paclitaxel -
motesanib
Scagliottib MONET1, 2012motesanib plus carboplatin/paclitaxel -
pazopanib
Scagliotti, 2013pazopanib pemetrexed -
sorafenib
Scagliotti, 2010sorafenibplacebo -
Spigel, 2011sorafenib and erlotinib erlotinib -
Wakelee, 2012sorafenib -
Paz-Ares, 2012sorafenib -
sunitinib
Scagliottia, 2012Sunitinib plus erlotinib erlotinib -
Groen, 2013sunitinib erlotinib -
Heist CALGB 30704 (Alliance): , 2014sunitinib pemetrexed -
vandetanib
Heymach, 2007 vandetanib plus docetaxel placebo plus docetaxel -
Natale, 2009Vandetanib versus gefitinib -
de Boer, 2011Vandetanib plus pemetrexed -
Natale, 2011Vandetanib gefitinib -
Lee ZEPHYR, 2012Vandetanib placebo -
Aisner, 2013vandetanib -
Ahn, 2013vandetanib maintenance -

antifolates

pemetrexed
Hanna, 2004pemetrexeddocetaxel -
Chen, 2008pemetrexeddocetaxel -
Smit, 2009pemetrexed plus carboplatinpemetrexedSuggesting
Socinski, 2010pemetrexed plus carboplatindocetaxel plus carboplatin - NCT00308750
Jose, 2011pemetrexed plus carboplatindocetaxel plus carboplatin -
Li, 2012pemetrexeddocetaxel -
Sun, 2013pemetrexeddocetaxel - NCT00391274
vandetanib
De Boer, 2011vandetanib plus pemetrexedpemetrexedNegative

CDK (cyclin-dependent kinase) inhibitor

abemaciclib
JUNIPER, 2018abemacicliberlotinib2nd line Risk of bias - NCT02152631

EGFR inhibitors

afatinib
LUX-LUNG 3, 2015afatinibcisplatin-based chemotherapy -
LUX-LUNG 6, 2015afatinibcisplatin-based chemotherapy -
1200.34 ongoing afatinibChemotherapy - NCT01121393
1200.42 ongoing afatinibchemotherapy - NCT01085136
1200.32 ongoing afatinibCisplatin/Pemetrexed - NCT00949650
LUX-LUNG 8 ongoing afatinibErlotinib - NCT01523587
LUX-LUNG 1 ongoing afatinibplacebo - NCT00656136
alectinib
ALEX, 2017alectinibcrizotinib1L Risk of bias ConclusiveNCT02075840
YO29449 ongoing alectinibcrizotinib - NCT02838420
MO29750 ongoing alectinibpremetrexed or docetaxel - NCT02604342
brigatinib
ALTA-1L ongoing brigatinibcrizotinib - NCT02737501
ceritinib
ASCEND-4, 2017ceritinibchemotherapy1L Risk of bias SuggestingNCT01828099
ASCEND 5, 2017ceritinibpemetrexed or docetaxel2L after crizotinib failure - NCT01828112
cetuximab
Butts, 2007cetuximabCT alone -
Rosell, 2008cetuximab + CTCT alone -
FLEX (Pirker), 2009cetuximab + CTCT aloneSuggestingNCT00148798
Lynch, 2010cetuximabCTNegative
crizotinib
Shaw, 2013crizotinibchemotherapy2L Risk of bias SuggestingNCT00932893
PROFILE 1014, 2014crizotinibchemotherapy1L Risk of bias SuggestingNCT01154140
A8081029 ongoing crizotinibchemotherapy Risk of bias - NCT01639001
E4512 ongoing crizotinibplaceboadjuvant Low risk of bias - NCT02201992
dacomitinib
ARCHER 1050dacomitinibgefitinib - NCT01774721
erlotinib
OPTIMAL erlotinibPlatinum-based CTSuggesting NCT00874419
EUTRACerlotinibPlatinum-based CTSuggesting NCT00446225
TITANerlotinibPlatinum-based CTNegative NCT00556322
TRIBUTE (Herbst)erlotinib + Platinum-based CTPlatinum-based CTNegative
Gatzemeier erlotinib + Platinum-based CTPlatinum-based CTNegative
Mok erlotinib + Platinum-based CTPlatinum-based CTSuggesting
SATURN (Cappuzzo)erlotinib + Platinum-based CTPlatinum-based CTSuggesting NCT00556712
Boutsikouerlotinib + Platinum-based CTPlatinum-based CTNegative
Lee erlotinib + Platinum-based CTPlatinum-based CTSuggesting NCT00550173
Stinchcombeerlotinib + Platinum-based CTPlatinum-based CTNegative
FASTACT-2 (Wu) erlotinib + Platinum-based CTPlatinum-based CTSuggesting NCT00883779
gefitinib
West Japangefitinib -
Northeast Japangefitinib -
IPASSgefitinibcarboplatin/paclitaxel1L -
First Signalgefitinibgemcitabine and cisplatin1L -
INTACT 1.gefitinib + gemcitabine/cisplatinplacebo + gemcitabine / cisplatin1L -
Kris, 2003gefitinibgefitinib2L -
INTACT 2, 2004gefitinib paclitaxel and carboplatinpaclitaxel and carboplatin1L -
Tsuboi, 2005gefitinibplacebo -
SIGN (Cufer), 2006gefitinibdocetaxel2LNegative
ISEL, 2006gefitinibplacebo2L -
V-15-32 (Maruyama), 2008gefitinibdocetaxel2LSuggesting
INTEREST (Kim), 2008gefitinibdocetaxel2LNegative
SWOG S0023 (Kelly), 2008gefitinibplacebo -
INVITE (Crinò), 2008gefitinibvinorelbine1L - NCT00256711
IPASS (Mok), 2009gefitinibcarboplatin-paclitaxel1L - NCT00322452
Goss, 2009gefitinibplacebo1L -
Maemondo, 2010gefitinibcarboplatin-paclitaxel2L - UMIN-CTR C000000376
WJTOG3405 (Mitsudomi), 2010gefitinibcisplatin plus docetaxel -
WJTOG0203 (Takeda), 2010gefitinibcontinued platinum-doublet chemotherapy -
ISTANA (Lee), 2010gefitinibdocetaxel2LSuggesting
IFCT-0301 study (Morère), 2010gefitinibdocetaxel -
EORTC 08021/ILCP 01/03, 2011gefitinibplacebo2L - NCT00091156
INFORM; C-TONG 0804, 2012gefitinibplacebo - NCT00770588
CTONG0806 (Yang), 2013gefitinib -
NEJ002, 2013gefitinibcarboplatin-paclitaxel1L -
NCIC CTG BR19 (Goss), 2013gefitinibplacebo -
osimertinib
FLAURA, 2017osimertinibplacebo1L Low risk of bias Suggesting NCT02296125
AURA 3, 2017osimertinibplatinum-based therapy plus pemetrexed 2LSuggestingNCT02151981

immune checkpoint inhibition

atezolizumab
POPLAR Phase 2 atezolizumab, 2016atezolizumabdocetaxel2L Exploratory NegativeNCT01903993
OAK, 2016atezolizumabdocetaxel2L Risk of bias SuggestingNCT02008227
IMpower150 (WT), 2018atezolizumab + bevacizumabbevacizumab (on top platinum-based CT)1L Risk of bias SuggestingNCT02366143
IMpower150 (Teff), 2018atezolizumab + bevacizumabbevacizumab (on top platinum-based CT)1L, TeffSuggestingNCT02366143
IMpower 010 ongoing atezolizumabBest Supportive Care - NCT02486718
IMpower 210 ongoing atezolizumabdocetaxel - NCT02813785
IMpower 133 ongoing atezolizumab + platinum-based CTplatinum-based CT1L - NCT02763579
IMpower 132 ongoing atezolizumab + platinum-based CTplatinum-based CT1L - NCT02657434
IMpower 131 ongoing atezolizumab + platinum-based CTplatinum-based CT - NCT02367794
GO29432 ongoing atezolizumabplatinum-based CT1L Risk of bias - NCT02409355
IMpower 110 ongoing atezolizumabplatinum-based CT1L Risk of bias - NCT02409342
avelumab
JAVELIN Lung 200 ongoing avelumabdocetaxel2L, PDL1 positive Risk of bias - NCT02395172
JAVELIN Lung 100 ongoing avelumabplatinum-based CT1L, PDL1 positive Risk of bias - NCT02576574
durvalumab
PACIFIC, 2017durvalumabplacebomaintenance Low risk of bias ConclusiveNCT02125461
ARCTIC PD-L1 negative, 2018durvalumab + tremelimumabStandard of Care3L, PD-L1 negative - NCT02352948
NEPTUNE ongoing durvalumab + tremelimumabplatinum-based CT1L Risk of bias - NCT02542293
CAURAL ongoing durvalumab + osimertinibosimertinib2L after EGFR TKI, T790M positive Risk of bias - NCT02454933
NCT02273375 ongoing durvalumabplaceboadjuvant Low risk of bias - NCT02273375
ARCTIC PD-L1 positive ongoing durvalumabStandard of Care>2L, PDL1 positive Risk of bias - NCT02352948
MYSTIC (combination) ongoing durvalumab +tremelimumabStandard of Care1L Risk of bias - NCT02453282
MYSTIC (monotherapy) ongoing durvalumabStandard of Care1L Risk of bias - NCT02453282
ipilimumab
phase 2 (phased ipilimumab), 2012ipilimumab + chemotherapyplacebo + chemotherapy -
Reck, 2016ipilimumab + chemotherapyplacebo + chemotherapySCLC - NCT01450761
Govindan, 2017ipilimumab + chemotherapyplacebo + chemotherapy1L Low risk of bias NegativeNCT01285609
nivolumab
CheckMate 057, 2015nivolumabdocetaxel2L, non squamous Risk of bias SuggestingNCT01673867
CheckMate 017, 2015nivolumabdocetaxel2L, squamous Risk of bias SuggestingNCT01642004
CheckMate 026, 2016nivolumabplatinum-based CT1L, PDL1 positive Risk of bias NegativeNCT02041533
CheckMate 227 (High Tumor Mutational Burden), 2018nivolumab + ipilimumabplatinum-based CT1L, hi TMB Risk of bias SuggestingNCT02477826
CheckMate 227 (nivolumab + CT), 2018nivolumab + CTplatinum-based CT1L, PDL1 negatifSuggestingNCT02477826
CheckMate 331 ongoing nivolumabCT - NCT02481830
CheckMate 078 ongoing nivolumabdocetaxel - NCT02613507
CheckMate 153 ongoing nivolumab for 1 yearnivolumab2L Risk of bias - NCT02066636
Checkmate 032 ongoing nivolumab + ipilimumabnivolumab - NCT01928394
CheckMate 451 ongoing nivolumabplacebo - NCT02538666
CheckMate 722 ongoing nivolumab + ipilimumabplatinum-based CT Risk of bias - NCT02864251
CheckMate 227 (nivolumab alone), 2018 ongoing nivolumabplatinum-based CT1L Risk of bias - NCT02477826
pembrolizumab
Keynote 010 2mg, 2015pembrolizumab 2mgdocetaxel2L, PD-L1 positive Risk of bias SuggestingNCT01905657
Keynote 010 10mg, 2015pembrolizumab 10mgdocetaxel2L, PD-L1 positive Risk of bias SuggestingNCT01905657
Keynote 024, 2015pembrolizumabplatinum-based CT1L, PDL1 positive Risk of bias SuggestingNCT02142738
KEYNOTE-021 phase 2, 2016pembrolizumab + platinum-based CTplatinum-based CT1L nonsquamous Exploratory SuggestingNCT02039674
Keynote 042 (>=1%), 2018pembrolizumabplatinum-based CT1L, PDL1 positive Risk of bias SuggestingNCT02220894
Keynote 189, 2018pembrolizumab + platinum-based CTplatinum-based CT1L PD-L1 positive nonsquamous Low risk of bias ConclusiveNCT02578680
Keynote 407, 2018pembrolizumanb + CTplatinum-based CT1L squamous Risk of bias SuggestingNCT02775435
Keynote 042 (>=50%), 2018pembrolizumabplatinum-based CT1L, PDL1 positiveSuggestingNCT02220894
Keynote 042 (>=20%), 2018pembrolizumabplatinum-based CT1L, PDL1 positive Risk of bias SuggestingNCT02220894

Taxanes

docetaxel
Camps weekly docetaxel3-weekly docetaxel -
Schuette weekly docetaxel3-weekly docetaxel -
Gervais weekly docetaxel3-weekly docetaxel -
Lai weekly docetaxel3-weekly docetaxel -
Chen weekly docetaxel3-weekly docetaxel -
TAX 317 (Shepherd) 100mg/m2, 2000docetaxel -
TAX 320 100mg/m2, 2000docetaxel -
Esteban, 2003paclitaxel 80mg/m2m2docetaxel 36 mg/ -
DISTAl 01 (Gridelli) , 2004weekly docetaxel3-weekly docetaxel -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons